1296136-93-0

Upstream product

• 408538-69-2 4-piperidin-4-ylbutyric acid methyl ester 
• 98-88-4 benzoyl chloride 

Downstream Products

• 1041756-57-3 [4-(4-aminobutyl)-1-piperidinyl](phenyl)methenone 
• 1296137-02-4 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(3-nitrophenyl)acrylamide 
• 1296137-03-5 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(1-(4-hydroxy-3-(hydroxymethyl)butyl)-1H-pyrrol-2-yl)acrylamide 
• 1296137-04-6 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(1-(4-hydroxy-3-(hydroxymethyl)butyl)-1H-pyrazol-4-yl)acrylamide 
• 1296137-05-7 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(1-(4-hydroxy-3-(hydroxymethyl)butyl)-1H-imidazol-4-yl)acrylamide 
• 1296137-06-8 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(1-(4-hydroxy-3-(hydroxymethyl)butyl)-1H-indol-3-yl)acrylamide 
• 1296137-07-9 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(1-methyl-1H-pyrrol-2-yl)acrylamide 
• 1296137-08-0 (E)-3-(2-aminophenyl)-N-(4-(1-benzoylpiperidin-4-yl)butyl)acrylamide 
• 1296137-09-1 (E)-3-(3-aminophenyl)-N-(4-(1-benzoylpiperidin-4-yl)butyl)acrylamide 
• 1041756-51-7 C₁₆H₂₃NO₂ 
• 1296137-13-7 C₁₇H₂₅NO₄S 
• 1296137-14-8 2-{4-[1-(phenylcarbonyl)piperidin-4-yl]butyl}-1H-isoindole-1,3(2H)-dione 
• 1296136-94-1 (E)-N-(4-(1-benzoylpiperidin-4-yl)butyl)-3-(pyrimidin-5-yl)acrylamide 
• 1296136-95-2 (E)-3-(2-aminopyrimidin-5-yl)-N-(4-(1-benzoylpiperidin-4-yl)butyl)acrylamide 

Relevant academic research and scientific papers

Alkyl piperidine and piperazine hydroxamic acids as HDAC inhibitors

We report here the strategy used in our research group to find a new class of histone deacetylase (HDAC) inhibitors. A series of N-substituted 4-alkylpiperazine and 4-alkylpiperidine hydroxamic acids, corresponding to the basic structure of HDAC inhibitors (zinc binding moiety-linker-capping group) has been designed, prepared, and tested for HDAC inhibition. Linker length and aromatic capping group connection were systematically varied to find the optimal geometric parameters. A new series of submicromolar inhibitors was thus identified, which showed antiproliferative activity on HCT-116 colon carcinoma cells.

Design, synthesis and X-ray crystallographic study of NAmPRTase inhibitors as anti-cancer agents

NAmPRTase (PBEF/Visfatin) plays a pivotal role in the salvage pathway of NAD+ biosynthesis. NAmPRTase has been an attractive target for anti-cancer agents that induce apoptosis of tumor cells via a declining plasma NAD+ level. In this report, a series of structural analogs of FK866 (1), a known NAmPRTase inhibitor, was synthesized and tested for inhibitory activities against the proliferation of cancer cells and human NAmPRTase. Among them, compound 7 showed similar anti-cancer and enzyme inhibitory activities to compound 1. Further investigation of compound 7 with X-ray analysis revealed a co-crystal structure in complex with human NAmPRTase, suggesting that Asp219 in the active site of the enzyme could contribute to an additional interaction with the pyrrole nitrogen of compound 7.